6 results
Heparin, Fondaparinux, and Novel Oral Anticoagulants - Pathophysiology

Anticoagulation with parenteral (intravenous or subcutaneous) and oral anticoagulants
Anticoagulants - Pathophysiology ... accelerates the bridging ... #Pharmacology #Pathophysiology ... #UFH #DOAC #Dabigatran ... #Fondaparinux #NOAC
Patient risk stratification algorithm for the treatment of cancer-associated thrombosis.

Currently, edoxaban and rivaroxaban are the only
stratification algorithm ... anticoagulants (DOACs ... molecular weight heparin ... #DOAC #VTE #Malignancy ... #Cancer #Algorithm
Summary of Coagulation Deficiencies
Inherited:
 • Hemophilia A - Deficiency of Factor VIII
 • Hemophilia B -
Summary of Coagulation ... Medications - Heparin ... LMWH, warfarin, DOACs ... most common) - Malignancy ... EricsMedicalLectures/ #Coagulation
Treatment algorithm for VTE in Malignancy

(A) Suggested treatment algorithm for symptomatic and incidental DVT or PE
Treatment algorithm ... for VTE in Malignancy ... DOAC, direct oral ... low-molecular-weight heparin ... #DOAC #VTE #Malignancy
Disseminated Intravascular Coagulation (DIC) Overview

Increased Clotting and Consumption of Clotting Factors

Findings:
 • Bleeding
 • Recent history
Intravascular Coagulation ... trauma, sepsis, malignancy ... protein C and S Pathophysiology ... deficiency) • HIT: Heparin-PF4 ... 100mg/dL) - Heparin
Venous Thrombosis vs Arterial Thrombosis - Differential Diagnosis Framework

VENOUS THROMBOSIS

 • Acquired Risk Factors:
	- >48 hours
- Surgery - Malignancy ... TTP, APLS • Malignancy ... Hyperhomocysteinemia - Heparin-induced ... intravascular coagulation ... Venous #Arterial #pathophysiology